Abstract
We applied an established and commercially available serum proteomic classifier for survival after treatment with erlotinib (VeriStrat) in a blinded manner to pretreatment sera obtained from recurrent advanced NSCLC patients before treatment with the combination of erlotinib plus bevacizumab. We found that VeriStrat could classify these patients into two groups with significantly better or worse outcomes and may enable rational selection of patients more likely to benefit from this costly and potentially toxic regimen.
Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
Publication types
-
Clinical Trial, Phase I
-
Clinical Trial, Phase II
-
Multicenter Study
-
Research Support, N.I.H., Extramural
MeSH terms
-
Adult
-
Aged
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bevacizumab
-
Carcinoma, Non-Small-Cell Lung / diagnosis*
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Carcinoma, Non-Small-Cell Lung / physiopathology
-
Disease Progression
-
Disease-Free Survival
-
Erlotinib Hydrochloride
-
Female
-
Humans
-
Lung Neoplasms / diagnosis*
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / mortality
-
Lung Neoplasms / pathology
-
Lung Neoplasms / physiopathology
-
Male
-
Mass Spectrometry
-
Middle Aged
-
Neoplasm Recurrence, Local
-
Precision Medicine
-
Predictive Value of Tests
-
Proteome / classification
-
Proteome / metabolism
-
Quinazolines / administration & dosage
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Proteome
-
Quinazolines
-
Bevacizumab
-
Erlotinib Hydrochloride